These ASX growth shares are top buys: broker

If you’re a growth investor on the lookout for some new portfolio additions, then read on!

That’s because listed below are two ASX growth shares that analysts at Morgans are feeling very bullish on right now.

Here’s what you need to know about these buy-rated growth shares:

Aristocrat Leisure Limited (ASX: ALL)

The first ASX growth share for investors to look at is Aristocrat Leisure. It is a leading gaming technology company with a range of world-class businesses involved in poker machines, digital/mobile games, and real money gaming.

Morgans is feeling very positive about the company’s “long-term growth potential, given its superior capitalisation and strong ability to invest in the development of its land-based and digital gaming businesses.” The broker also highlights its “high cash conversion rate and ROCE, despite running a capital-light model.”

Its analysts currently have an add rating and a $43 price target on Aristocrat’s shares. This compares to its current share price of $38.34.

ResMed Inc (ASX: RMD)

Another ASX growth share that could be a buy for growth investors this month is ResMed. It is a medical device company with a focus on the sleep treatment market. This includes medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders such as sleep-disordered breathing and chronic obstructive pulmonary disease.

Morgans is also very positive on the company and believes it is well-placed for the future “as it builds a unique, patient-centric, connected-care digital platform that addresses the main pinch points across the healthcare value chain.”

The broker currently has an add rating and a $37.80 price target on the company’s shares. This compares to the latest ResMed share price of $32.39.